Creation of a database to assess effects of omega-3, omega-6 and total polyunsaturated fats on health: Methodology for a set of systematic reviews

BMJ Open

Volumn 9, Issue 5, 2019, Pages

  Hooper, Lee ^a   Abdelhamid, Asmaa ^a   Brainard, Julii ^a   Deane, Katherine H O ^b   Song, Fujian ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

database of trials; fatty acids; meta analysis as topic; omega 3; omega 6; systematic review methodology; unsaturated

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN A; LINOLEIC ACID; LINOLENIC ACID; LIPID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHATIDYLCHOLINE; POLYUNSATURATED FATTY ACID; UNSATURATED FATTY ACID;

ANXIETY DISORDER; ASSESSMENT OF HUMANS; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; COGNITIVE DEFECT; DEPRESSION; DIABETES MELLITUS; DRUG EFFECT; EMBASE; FUNCTIONAL STATUS; GLUCOSE METABOLISM; GRADING RECOMMENDATION ASSESSMENT DEVELOPMENT AND EVALUATION; HEALTH STATUS; HUMAN; INFLAMMATORY BOWEL DISEASE; LONG TERM CARE; MALIGNANT NEOPLASM; MEDLINE; META ANALYSIS; MORTALITY RATE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; WORLD HEALTH ORGANIZATION; CHRONIC DISEASE; FACTUAL DATABASE; HEALTH BEHAVIOR;

CHRONIC DISEASE; DATABASES, FACTUAL; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FATTY ACIDS, UNSATURATED; HEALTH BEHAVIOR; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85066878329     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2019-029554     Document Type: Review

References (31)

1. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018;304. 11:CD003177.
2. Abdelhamid AS, Martin N, Bridges C, et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018;11:CD012345.
3. Hooper L, Al-Khudairy L, Abdelhamid AS, et al. Omega-6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018;11:CD011094.
4. Brown TJ, Brainard JS, Song F, et al. Omega-3, omega-6 and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review of randomised controlled trials. Br Med J 2018. submitted.
5. Hanson S, Biswas P, Jimoh O, et al. Dietary polyunsaturated fat for prevention and treatment of depression and anxiety. Prospero 2017:CRD42017056092.
6. Jimoh OF, Brainard J, Deane KA, et al. Dietary polyunsaturated fat for prevention and treatment of neurocognitive disorders. Prospero 2017:CRD42017019049.
7. Hanson S, Thorpe G, Winstanley L, et al. Effects of supplementary dietary polyunsaturated fat on cancer incidence. Prospero 2017:CRD42017056109.
8. Thorpe G, Ajabnoor S, Ahmed Z, et al. Dietary polyunsaturated fat for prevention and treatment of inflammatory bowel disease. Prospero 2017:CRD42017068704.
9. Brown T, Song F, Wang X, et al. Dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus. Prospero 2017:CRD42017064110.
10. Abdelhamid A, Hooper L, Welch A. Polyunsaturated fatty acids for musculoskeletal health and functional status in older adults. Prospero 2017:CRD42017079211.
11. Browning LM, Walker CG, Mander AP, et al. Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr 2012;96:748-58.
12. Al-Khudairy L, Hartley L, Clar C, et al. Omega 6 fatty acids for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2015;11:CD011094.
13. Hooper L, Harrison RA, Summerbell CD, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev 2004;20.
14. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration, 2011. www. cochrane-handbook. org.
15. Bowman L, Mafham M, Wallendszus K, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med 2018;379:1540-50.
16. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22.
17. Hull MA, Sprange K, Hepburn T, et al. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 2 factorial trial. Lancet 2018;392:2583-94.
18. Manson JE, Cook NR, Lee IM, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med 2019;380:23-32.
19. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011): The Cochrane Collaboration, 2011.
20. Review Manager 5 (RevMan 5) [program]. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2014.
21. Deane KHO, Jimoh OF, Biswas P, et al. Omega-3, omega-6 and total polyunsaturated fat for prevention and severity of depression and anxiety: a systematic review and meta-analysis of RCTs. 2018. submitted.
22. Abdelhamid AS, Hooper L, Sivakaran R, et al. Omega-3, omega-6 and total polyunsaturated fat for musculoskeletal health and functional status in older adults: a systematic review and metaanalysis of RCTs. 2018. submitted.
23. Higgins JPT, Altman DG, Jacobotcsmg S, et al. Chapter 8: Assessing risk of bias in included studies. Higgins Jpt GS, ed. Cochrane handbook for systematic reviews of interventions Version 510: The Cochrane Collaboration, 2011. www. handbook. cochrane. org
24. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
25. Savovi J, Jones H, Altman D, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of metaepidemiological studies. Health Technol Assess 2012;16:1-82.
26. Wood L, Egger M, Gluud LL, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601-5.
27. Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015-26.
28. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757-61.
29. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
30. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-90.
31. GRADEpro GDT. GRADEpro GuidelineDevelopment Tool [program]: gradepro. org: McMaster University (developed by Evidence Prime, Inc), 2015.